AR048723A1 - Derivados de indol como moduladores selectivos del receptor de androgenos (sarms) - Google Patents
Derivados de indol como moduladores selectivos del receptor de androgenos (sarms)Info
- Publication number
- AR048723A1 AR048723A1 ARP050101747A ARP050101747A AR048723A1 AR 048723 A1 AR048723 A1 AR 048723A1 AR P050101747 A ARP050101747 A AR P050101747A AR P050101747 A ARP050101747 A AR P050101747A AR 048723 A1 AR048723 A1 AR 048723A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- hydrogen
- halogen
- group
- substituted
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 239000003098 androgen Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 48
- 229910052739 hydrogen Inorganic materials 0.000 abstract 28
- 239000001257 hydrogen Substances 0.000 abstract 28
- 150000002431 hydrogen Chemical group 0.000 abstract 19
- 229910052736 halogen Inorganic materials 0.000 abstract 13
- 150000002367 halogens Chemical group 0.000 abstract 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- -1 hydroxy, carboxy Chemical group 0.000 abstract 7
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000001307 androgen receptors Human genes 0.000 abstract 1
- 108010080146 androgen receptors Proteins 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Composiciones farmacéuticas que los contienen y su uso en el tratamiento de trastornos y afecciones moduladas por el receptor de androgenos. Reivindicacion 1: Un compuesto de formula (1), X se selecciona del grupo integrado por O, S y NR1; R1 se selecciona del grupo integrado por hidrogeno, alquilo inferior, alquilo inferior fluorado, -SO2-(alquilo inferior), -SO2-fenilo, -SO2-tolilo, -(CH2)-(alquilo inferior fluorado), -(alquilo inferior)-CN, -(alquilo inferior)-C(O)-O-(alquilo inferior), - (alquilo inferior)-O-(alquilo inferior) y -(alquilo inferior)-S(O)0-2-(alquilo inferior); R4 se selecciona del grupo integrado por hidrogeno, halogeno, alquilo inferior, alquenilo inferior, alquinilo inferior y ciano; donde el alquilo inferior, alquenilo inferior o alquinilo inferior está opcionalmente sustituido sobre el átomo de carbono terminal con -Si(alquilo inferior)3; a es un entero de 0 a 4; R5 se selecciona del grupo integrado por halogeno, hidroxi, carboxi, alquilo inferior, alquilo inferior sustituido con halogeno, alcoxi inferior, alcoxi inferior sustituido con halogeno, ciano, nitro, amino, alquilamino inferior, di(alquilo inferior)amino, -C(O)-(alquilo inferior), -C(O)-(alcoxi inferior), -C(O)-N(RA)2, -S(O)0-2- (alquilo inferior), -SO2-N(RA)2, -N(RA)-C(O)-(alquilo inferior), -N(RA)-C(O)-(alquilo inferior sustituido con halogeno) y arilo; donde cada RA se selecciona independientemente de hidrogeno o alquilo inferior; donde el arilo está opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados de halogeno, hidroxi, carboxi, alquilo inferior, alquilo inferior sustituido con halogeno, alcoxi inferior, alcoxi inferior sustituido con halogeno, ciano, nitro, amino, alquilamino inferior o di(alquilo inferior)amino; b es un entero de 0 a 1; c es un entero de 0 a 1; R7 se selecciona del grupo integrado por hidrogeno, alquilo inferior y -Si(alquilo inferior)3; R2 se selecciona del grupo integrado por hidrogeno, alquilo inferior, alquilo inferior sustituido con halogeno y -(CH2)1-4-Z-R6; R3 se selecciona del grupo integrado por alquilo inferior, alquilo inferior sustituido con halogeno y -(CH2)1-4-Z-R6; donde cada Z se selecciona independientemente del grupo integrado por -S(O)0-2-, -O-, -O-C(O)-, -NH- y -N(alquilo inferior)-; donde cada R6 se selecciona independientemente del grupo integrado por alquilo inferior, alquilo inferior sustituido con halogeno, alquenilo inferior, arilo, aralquilo, bifenilo, cicloalquilo, cicloalquil-(alquilo inferior), heteroarilo y heteroaril-(alquilo inferior); donde el grupo cicloalquilo, arilo o heteroarilo, ya sea solo o como parte de un grupo sustituyente, está opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados de halogeno, hidroxi, carboxi, alquilo inferior, alquilo inferior sustituido con halogeno, alcoxi inferior, ciano, nitro, amino, alquilamino inferior, di(alquilo inferior)amino, -S(O)0-2-(alquilo inferior) y -SO2-N(RA)2; siempre que cuando Z es O, NH o N(alquilo inferior) entonces R6 es diferente de alquenilo inferior; siempre que además cuando R2 es metilo, entonces R3 es diferente de metilo; siempre que además cuando X es NR1, R1 es hidrogeno o alquilo inferior, b es 1, c es 0, R4 es hidrogeno, R7 es hidrogeno, a es 0 y R2 es CF3, entonces R3 es diferente de CF3; siempre que además cuando X es NH, R4 es metilo, b es 0, c es 0, R7 es hidrogeno, a es 0 y R2 es metilo, entonces R3 es diferente de CF3; siempre que además cuando X es NR1, R1 es hidrogeno o alquilo inferior, R4 es hidrogeno o metilo, b es 0, a es 0, R7 es hidrogeno, a es 0 y R2 es hidrogeno, o metilo, entonces R3 es diferente de -(CH2)1-2N(RA)-(alquilo inferior) o -(CH2)3-N(RA)-(bencilo); siempre que además cuando X es NH, R4 es hidrogeno, b es 1, c es 0, R7 es hidrogeno, a es 0 y R2 es hidrogeno, entonces R3 es diferente de -(CH2)-NH-(alquilo inferior); siempre que además cuando X es NH, R4 es hidrogeno, a es 0, R7 es hidrogeno, b es 0, c es 0 y R2 es CF3, entonces R3 es diferente de -CH2-O-C(O)-CH3; siempre que además cuando X es NH, R4 es hidrogeno, a es 0, R7 es hidrogeno, b es 1, c es 1 y R2 es hidrogeno, entonces R3 es diferente de -CH2-O-C(O)- CH3; siempre que además cuando X es NR1, R1 es hidrogeno o metilo, R4 es hidrogeno o metilo, b es 0, c es 0, R7 es hidrogeno y R2 es hidrogeno, entonces R3 es diferente de -CH2-O-alquilo inferior o -CH2-O-bencilo; siempre que además cuando X es O, R4 es hidrogeno, b es 0, c es 0, R7 es hidrogeno y R2 es hidrogeno, entonces R3 es diferente de CH2-O-fenilo, donde el fenilo está opcionalmente sustituido con uno a dos sustituyentes independientemente seleccionados de alquilo inferior, alquilo inferior sustituido con hidroxi, carboxi y -C(O)-(alcoxi inferior); o su sal aceptable para uso farmacéutico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56748904P | 2004-05-03 | 2004-05-03 | |
| US11/096,673 US7288553B2 (en) | 2004-05-03 | 2005-04-01 | Indole derivatives as selective androgen receptor modulator (SARMS) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048723A1 true AR048723A1 (es) | 2006-05-17 |
Family
ID=34964755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101747A AR048723A1 (es) | 2004-05-03 | 2005-05-02 | Derivados de indol como moduladores selectivos del receptor de androgenos (sarms) |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7288553B2 (es) |
| EP (2) | EP1771413B1 (es) |
| JP (1) | JP4917018B2 (es) |
| CN (2) | CN102091068B (es) |
| AR (1) | AR048723A1 (es) |
| AT (1) | ATE525354T1 (es) |
| AU (1) | AU2005243239C1 (es) |
| CA (1) | CA2565205A1 (es) |
| ES (1) | ES2371170T3 (es) |
| MY (1) | MY143211A (es) |
| TW (1) | TWI359138B (es) |
| WO (1) | WO2005110985A2 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7435837B2 (en) * | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
| US20050261347A1 (en) * | 2003-10-24 | 2005-11-24 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
| EP1771413B1 (en) * | 2004-05-03 | 2011-09-21 | Janssen Pharmaceutica NV | Benzofuran derivatives as selective androgen receptor modulators (sarms) |
| PT2181990E (pt) * | 2007-08-31 | 2012-10-16 | Astellas Pharma Inc | Derivado de piperidina |
| DK2222636T3 (da) | 2007-12-21 | 2013-06-03 | Ligand Pharm Inc | Selektive androgenreceptormodulatorer (SARMS) og anvendelser deraf |
| JP2009173594A (ja) * | 2008-01-25 | 2009-08-06 | Sumitomo Chemical Co Ltd | アミロイドβタンパク質の蓄積を抑制するための医薬組成物 |
| JP5609150B2 (ja) * | 2009-02-27 | 2014-10-22 | アステラス製薬株式会社 | ピペリジン誘導体 |
| CA2788907A1 (en) * | 2010-02-04 | 2011-08-11 | Radius Health, Inc. | Selective androgen receptor modulators |
| ES2550319T3 (es) | 2010-09-28 | 2015-11-06 | Radius Health, Inc | Moduladores selectivos del receptor de andrógenos |
| CN104619693B (zh) | 2012-07-17 | 2019-08-13 | 葛兰素史克知识产权第二有限公司 | 作为选择性雄激素受体调节剂的吲哚腈类 |
| EP3094323A4 (en) | 2014-01-17 | 2017-10-11 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
| EP4066827A1 (en) | 2016-06-22 | 2022-10-05 | Ellipses Pharma Ltd | Ar+ breast cancer treatment methods |
| EP4223293A1 (en) * | 2020-09-30 | 2023-08-09 | Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology | Pharmaceutical composition for treatment of prostate cancer or breast cancer |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1088059B (de) * | 1957-07-11 | 1960-09-01 | Ciba Geigy | Verfahren zur Herstellung von in 1- und 9-Stellung substituierten, quaternaeren ª†-Carboliniumsalzen |
| US3326935A (en) * | 1964-01-07 | 1967-06-20 | Smith Kline French Lab | (2-amino-1-hydroxyethyl)-thianaphthenes |
| BE663926A (es) * | 1964-05-20 | |||
| GB1123974A (en) * | 1964-10-05 | 1968-08-14 | Belge Produits Chimiques Sa | Benzofuran derivatives and process for preparing the same |
| US3929836A (en) * | 1965-05-11 | 1975-12-30 | Hoffmann La Roche | 2-(2-Lower alkylamino-1-hydroxy-ethyl)-substituted benzofurans |
| GB1174411A (en) * | 1966-03-02 | 1969-12-17 | Aspro Nicholas Ltd | Novel Benzothiophen Compounds, Compositions containing them and processes for their manufacture |
| TR16784A (tr) * | 1971-04-20 | 1973-05-01 | Hoffmann La Roche | Sikroplopan tuervleri |
| GB1346912A (en) * | 1973-04-20 | 1974-02-13 | Roche Products Ltd | Substituted benzofurans |
| EP0029320B1 (en) * | 1979-11-15 | 1985-07-10 | Beecham Group Plc | Secondary ethanol amines, their preparation and their use in pharmaceutical compositions |
| JPH04139177A (ja) * | 1989-12-28 | 1992-05-13 | Dainippon Ink & Chem Inc | フラルベンゾキノン誘導体及びその製造方法並びに制癌剤 |
| AU2274292A (en) * | 1991-07-09 | 1993-02-11 | Nippon Shinyaku Co. Ltd. | Benzofuran derivative and pharmaceutical composition |
| AU6581094A (en) * | 1993-04-22 | 1994-11-08 | Nippon Shinyaku Co. Ltd. | Benzofurancarboxylic acid derivative and pharmaceutical composition |
| US6160109A (en) * | 1995-10-20 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Preparation of phosphorothioate and boranophosphate oligomers |
| WO1997032870A1 (fr) * | 1996-03-08 | 1997-09-12 | Synthelabo | Derives de 2-aminoethyl-benzofurane, leur preparation et leur application en therapeutique |
| GB9610813D0 (en) * | 1996-05-23 | 1996-07-31 | Pharmacia Spa | Combinatorial solid phase synthesis of a library of benzufuran derivatives |
| JP2000109479A (ja) * | 1998-07-30 | 2000-04-18 | Japan Tobacco Inc | ジ置換マレイミド化合物及びその医薬用途 |
| JP3714093B2 (ja) * | 2000-02-29 | 2005-11-09 | アイシン精機株式会社 | 燃料電池 |
| AR030414A1 (es) * | 2000-04-03 | 2003-08-20 | Astrazeneca Ab | Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos |
| ES2321933T3 (es) * | 2000-08-24 | 2009-06-15 | University Of Tennessee Research Foundation | Moduladores selectivos del receptor de androgeno y metodos de uso de los mismos. |
| GB0106177D0 (en) * | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| US20030022868A1 (en) * | 2001-06-25 | 2003-01-30 | Dalton James T. | Selective androgen receptor modulators and methods of use thereof |
| BR0307782A (pt) * | 2002-02-19 | 2005-01-04 | Upjohn Co | Compostos azabiciclo para o tratamento de doença |
| ES2298508T3 (es) * | 2002-03-26 | 2008-05-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Mimeticos de glucocorticoides, metodos para prepararlos, composiciones farmaceuticas y sus usos. |
| JP4717005B2 (ja) * | 2003-11-20 | 2011-07-06 | イーライ リリー アンド カンパニー | ビタミンｄ受容体モジュレータ |
| ES2291981T3 (es) * | 2003-11-20 | 2008-03-01 | Eli Lilly And Company | Moduladores del receptor de la vitamina d. |
| GB0403148D0 (en) * | 2004-02-12 | 2004-03-17 | Smithkline Beecham Corp | Chemical compounds |
| EP1771413B1 (en) | 2004-05-03 | 2011-09-21 | Janssen Pharmaceutica NV | Benzofuran derivatives as selective androgen receptor modulators (sarms) |
| JP5070042B2 (ja) * | 2004-05-03 | 2012-11-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 選択的アンドローゲン受容体モジュレーター（ｓａｒｍｓ）としての新規インドール化合物 |
-
2005
- 2005-04-01 EP EP05732623A patent/EP1771413B1/en active Active
- 2005-04-01 AU AU2005243239A patent/AU2005243239C1/en not_active Ceased
- 2005-04-01 JP JP2007511373A patent/JP4917018B2/ja not_active Expired - Fee Related
- 2005-04-01 ES ES05732623T patent/ES2371170T3/es active Active
- 2005-04-01 EP EP09075147.0A patent/EP2078712B1/en not_active Not-in-force
- 2005-04-01 WO PCT/US2005/011062 patent/WO2005110985A2/en active Application Filing
- 2005-04-01 CA CA002565205A patent/CA2565205A1/en not_active Abandoned
- 2005-04-01 CN CN2010106206226A patent/CN102091068B/zh not_active Expired - Fee Related
- 2005-04-01 AT AT05732623T patent/ATE525354T1/de not_active IP Right Cessation
- 2005-04-01 US US11/096,673 patent/US7288553B2/en active Active
- 2005-04-01 CN CN2005800222364A patent/CN1980891B/zh not_active Expired - Fee Related
- 2005-04-29 MY MYPI20051936A patent/MY143211A/en unknown
- 2005-04-29 TW TW094113778A patent/TWI359138B/zh not_active IP Right Cessation
- 2005-05-02 AR ARP050101747A patent/AR048723A1/es not_active Application Discontinuation
-
2007
- 2007-09-20 US US11/858,621 patent/US7678926B2/en not_active Expired - Fee Related
-
2010
- 2010-01-20 US US12/690,349 patent/US8394971B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20080070970A1 (en) | 2008-03-20 |
| AU2005243239B2 (en) | 2012-04-26 |
| JP4917018B2 (ja) | 2012-04-18 |
| ES2371170T3 (es) | 2011-12-28 |
| MY143211A (en) | 2011-03-31 |
| EP1771413A2 (en) | 2007-04-11 |
| CN102091068B (zh) | 2012-09-19 |
| CN1980891B (zh) | 2011-03-09 |
| CN1980891A (zh) | 2007-06-13 |
| AU2005243239C1 (en) | 2013-10-24 |
| US20110021785A1 (en) | 2011-01-27 |
| AU2005243239A1 (en) | 2005-11-24 |
| US8394971B2 (en) | 2013-03-12 |
| EP1771413B1 (en) | 2011-09-21 |
| JP2007536226A (ja) | 2007-12-13 |
| US7678926B2 (en) | 2010-03-16 |
| EP2078712B1 (en) | 2015-06-10 |
| TW200604171A (en) | 2006-02-01 |
| TWI359138B (en) | 2012-03-01 |
| CN102091068A (zh) | 2011-06-15 |
| EP2078712A1 (en) | 2009-07-15 |
| CA2565205A1 (en) | 2005-11-24 |
| ATE525354T1 (de) | 2011-10-15 |
| US20050250740A1 (en) | 2005-11-10 |
| US7288553B2 (en) | 2007-10-30 |
| WO2005110985A3 (en) | 2006-04-27 |
| WO2005110985A2 (en) | 2005-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR048723A1 (es) | Derivados de indol como moduladores selectivos del receptor de androgenos (sarms) | |
| AR048643A1 (es) | Derivados de indol como moduladores selectivos de los receptores androgenicos (sarms) | |
| AR048644A1 (es) | Derivados del indol como moduladores selectivos de los receptores androgenicos (sarms) | |
| AR050966A1 (es) | Derivados de bencimidazol utiles como moduladores selectivos de receptores de androgenos (sarms) | |
| PE20220597A1 (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos | |
| ES2422204T3 (es) | Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS) | |
| AR050967A1 (es) | Derivados de bencimidazol utiles como moduladores de los receptores androgenicos (sarms) | |
| HRP20100283T8 (en) | Derivatives of n-' (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity | |
| AR113903A2 (es) | Derivados fungicidas de pirazol carboxamidas | |
| PE20070112A1 (es) | Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos | |
| ME01421B (me) | 5-supstituisani derivati kinazolinona kao protivtumorska sredstva | |
| CY1112283T1 (el) | Μεθοδος για την παρασκευη 17-βινυλ-τριφλικων ως ενδιaμεσα | |
| CO6260076A2 (es) | Derivados de uracilo o timina para el tratamiento de la hepatitis c | |
| MX2009012885A (es) | Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco | |
| PE20061290A1 (es) | Derivados de 1-benzil-indol-2-carboxamida | |
| RU2010106393A (ru) | Новые микробиоциды | |
| UY31950A (es) | Inhibidores de ciclopropil-polimerasa | |
| CO6140056A2 (es) | Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa | |
| AR074862A1 (es) | Derivados de heterociclo biciclicos y sus metodos de uso | |
| PE20070069A1 (es) | Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a | |
| MX2010007019A (es) | Compuestos de bencimidazol. | |
| CO5700763A2 (es) | Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra | |
| AR043055A1 (es) | Derivados de 1-(4-benzil-piperazin-1-il)-3- fenil-propenona | |
| AR114338A1 (es) | Herbicidas de carboxilato de piridina y pirimidina y métodos para su uso | |
| ECSP13012416A (es) | Derivados heterocíclicos fusionados como moduladores s1p |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |